We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
15 February 2021
On 24 December 2020 the Federal Court issued a decision in a patent infringement action pursuant to Section 6(1) of the Patented Medicines (Notice of Compliance) Regulations relating to silodosin (Allergan's Rapaflo) (Allergan Inc v Sandoz Canada Inc, 2020 FC 1189). Chief Justice Crampton found that Canadian Patent 2,507,002, relating to a capsule formulation of silodosin, was not invalid on the basis of obviousness, but not infringed as "the Sandoz Product does not contain 'granules' and does not involve 'granulating' or a 'wet granulation process'", all of which were found to be essential elements.
The court declined to consider the prosecution file history in determining whether certain claim elements were essential on the basis that Section 53.1 of the Patent Act permits admission of the prosecution history to rebut representations made by the patentee (Kissei in this case) in an action or application, not a licensee (Allergan in this case). The patentee made no representations to the court regarding construction.
For further information on this topic please contact Brandon Heard at Smart & Biggar by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar website can be accessed at www.smartbiggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.